Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasm Metastasis 5Prostatic Neoplasms 4Sarcoma 3Neoplasms 3Pancreatic Neoplasms 2Neuroblastoma 2Hodgkin Disease 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Soft Tissue Neoplasms 1Recurrent Uterine Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphangioleiomyomatosis 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Paclitaxel 4tocilizumab 2pembrolizumab 2atezolizumab 2zansecimab 1tivozanib 1temsirolimus 1spartalizumab 1ridaforolimus 1parsaclisib 1olaparib 1obinutuzumab 1motesanib diphosphate 1liposomal doxorubicin 1itacitinib 1epacadostat 1durvalumab 1birinapant 1Vertebroplasty 1Temozolomide 1TAK-981 1Ramucirumab 1Panobinostat 1Oxaliplatin 1Leucovorin 1Kyphoplasty 1IT-101 1INCB039110 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumors × temsirolimus × Clear all
NCT01369433 2020-09-01

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

AVEO Pharmaceuticals, Inc.

Phase NA Terminated
225 enrolled 7 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡